These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7483543)

  • 41. [The use of histamine H2 receptor blockaders in gastroenterology].
    Waldum HL; Petersen H
    Tidsskr Nor Laegeforen; 1983 Apr; 103(12):980-3. PubMed ID: 6136102
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of the novel histamine H2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]ethyl]-2-(methylsulfonyl) guanidine on gastric secretion and gastroduodenal ulcers in rats.
    Amagase K; Kato S; Yamamoto H; Okabe S
    Arzneimittelforschung; 1996 Feb; 46(2):177-84. PubMed ID: 8720310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mechanism of recurrence and relapse in peptic ulcer after drug therapy; gastric juice and gastric acid secretion].
    Nakaizumi A; Iishi H; Tatsuta M; Okuda S
    Nihon Rinsho; 1988 Jan; 46(1):102-6. PubMed ID: 2897480
    [No Abstract]   [Full Text] [Related]  

  • 44. [A gastroenterologist's choice: proton pump inhibitors of H2 histamine receptor blockers in the treatment of peptic ulcer].
    Morozov IA
    Klin Med (Mosk); 2001; 79(5):68-71. PubMed ID: 11510196
    [No Abstract]   [Full Text] [Related]  

  • 45. [Currents aspects of H2 receptor antagonists in the treatment of ulcers].
    Debongnie JC
    Acta Gastroenterol Belg; 1992; 55(5-6):415-22. PubMed ID: 1363166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The influence of antisecretory agents on the antral gastric mucosa in patients with duodenal ulcer].
    Rapoport SI; Raĭkhlin NT; Khutsishvili MB; Rasulov MI; Antonenko NI
    Klin Med (Mosk); 2006; 84(7):32-5. PubMed ID: 16924798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapy of peptic ulcer. H2 receptor blockers].
    Domschke W
    Verh Dtsch Ges Inn Med; 1988; 94():272-5. PubMed ID: 2905101
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

  • 49. [H2 receptor antagonists in the therapy of peptic ulcer disease].
    Dammann HG; Dau B; Dreyer M; Müller P; Simon B
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():136-45. PubMed ID: 2889298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long-term treatment of peptic ulcer with histamine H2 receptor blockaders: results of their use and new problems].
    Grigor'ev PIa; Isakov VA
    Klin Med (Mosk); 1991 Oct; 69(10):93-7. PubMed ID: 1685004
    [No Abstract]   [Full Text] [Related]  

  • 51. Evaluation of cimetidine (tagamet). An antagonist of hydrochloric acid secretion.
    Clayman CB
    JAMA; 1977 Sep; 238(12):1289-90. PubMed ID: 19635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of peptic ulcer with histamine H2-receptor antagonists].
    Radbil' OS
    Sov Med; 1977 Nov; (11):111-9. PubMed ID: 24276
    [No Abstract]   [Full Text] [Related]  

  • 53. [Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions].
    Spasov AA; Chernikov MV; Speranskaia AS; Zaĭchenko SI
    Eksp Klin Gastroenterol; 2005; (6):24-7, 111-2. PubMed ID: 17378382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolving perspectives on parenteral H2-receptor antagonist therapy. Symposium. Tucson, Arizona, April l0-11, 1987.
    Am J Med; 1987 Dec; 83(6A):1-88. PubMed ID: 2892404
    [No Abstract]   [Full Text] [Related]  

  • 55. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The endoscopic assessment of the effect of ranitidine and pirenzepine on the manifestations of the gastropathy induced by nonsteroidal anti-inflammatory preparations].
    Karateev AE; Murav'ev IuV; Nasonova VA
    Ter Arkh; 1997; 69(5):67-9. PubMed ID: 9235663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
    Chelvam P; Wong EC
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():75-81. PubMed ID: 2577478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The influence of proton-pump inhibitors on the healing process of peptic ulcers--electronic endoscopic study].
    Miyahara T; Kawaguchi A; Nogao S; Niwa H
    Nihon Rinsho; 1992 Jan; 50(1):98-103. PubMed ID: 1347335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. H2 receptor antagonists.
    Siepler JK; Campagna KD; Donahue PE; Bombeck CT
    Am J Hosp Pharm; 1978 Feb; 35(2):141-5. PubMed ID: 24338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Role of surgery in the therapy of peptic ulcer after arrival of H2-blocking drugs].
    Perri S; Amendolara M; Breda E; Todarello V; Gallo G; Pietrangeli F; Meneghini G; Gelmi GF
    G Chir; 1990 Sep; 11(9):466-70. PubMed ID: 1981139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.